EF Hutton Maintains Buy on Marinus Pharma, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert maintains a Buy rating on Marinus Pharma (NASDAQ:MRNS) but significantly lowers the price target from $23 to $3.
October 24, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
EF Hutton's analyst Jason Kolbert maintains a Buy rating on Marinus Pharma but drastically reduces the price target from $23 to $3, indicating a significant reassessment of the company's valuation.
The drastic reduction in the price target from $23 to $3 suggests a significant change in the analyst's outlook on Marinus Pharma's future performance. While the Buy rating is maintained, the new price target indicates a much lower expected valuation, which could lead to a negative short-term impact on the stock price as investors reassess their positions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100